Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study

NCT02184013 · tracked via the Priya Life Science Canada tracker

Sponsor

Ottawa Heart Institute Research Corporation

Phase

Not applicable

Started

2015-09-14

Last updated

2026-05-06

Condition(s) studied

Persistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

Catheter ablation

Catheter ablation: Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).

Study summary

This is a pilot study to assess the usefulness of ECG mapping, and enhanced MRI and PET scan imaging in identifying atrial fibrosis and arrhythmia circuits involved in persistent atrial fibrillation and in guiding an innovative AF catheter ablation strategy.

It is hypothesized that identifying these critical arrhythmia circuits and atrial fibrosis with enhanced imaging and performing an individualized innovative AF catheter ablation will result in higher procedural success rates.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age ≥18 years and ≤ 80 years; * Symptomatic persistent AF AND clinically indicated for AF catheter ablation * At least one episode of AF lasting more than 7 days, documented on 12-lead ECG, Holter monitor, 2-week loop monitor or trans-telephonic monitor (TTM) within 12 months of enrollment in the study * Able to provide informed consent. Exclusion Criteria: * History of previous catheter or surgical ablation for AF * Presence of intracardiac thrombus * contraindication to systemic oral anticoagulation therapy * Subjects with reversible causes of AF * Antero-posterior left atrial dimension \> 60 mm on echocardiography * Severe valvular disease (mitral/aortic stenosis or regurgitation); * Subjects that are pregnant or breastfeeding; * Chronic kidney disease and creatinine clearance \<50ml/min. * Contraindication to MRI Imaging (e.g. permanent pacemaker, metallic implants, etc)

Primary outcome measure(s)

Atrial Fibrillation (AF) Termination — During catheter ablation
AF termination resulting in restoration of sinus rhythm during ablation.

Trial sites (1)

Facility	City	Region	Status
University of Ottawa Heart Institute	Ottawa	Ontario

More Ottawa Heart Institute Research Corporation trials in Canada

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial Active, not recruiting

Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation Active, not recruiting

MAX - SHOCK Clinical Trial Recruiting

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm Recruiting

The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments Recruiting

Other trials for the same condition

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Recruiting

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation Active, not recruiting

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02184013 on ClinicalTrials.gov ↗ ← All trials in Canada